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Two anti-inflammatory peptides corresponding to a high amino acid similarity region between lipocortins were syn- 
thesized and tested on their ability to inhibit porcine pancreatic phospholipase &. Kinetic assays using monomeric and 
aggregated phospholipids did not reveal any phospholipase A, inhibitory activity. The peptides did not inhibit phospho- 
lipase A2 activity on monolayers of negatively charged substrate and did not prevent phospholipase 4 action on mixed 
micelles of l-stearoyl-2-arachidonoyl-sn-glycero-3-phosph~holine and sodiumdeoxycholate. Ultraviolet difference spec- 
troscopy did not show binding of the peptides to phospholipase 4. Therefore we conclude that these anti-inflammatory 
peptides do not inhibit pancreatic phospholipase A2 in vitro, in contrast o the results recently published [(1988) Nature 
335, 7267301. 
Lipocortin; Phospholipase A,; Synthetic peptide 
1. INTRODUCTION 
The production of the prostaglandins, leuko- 
trienes and related eicosanoids depends on the 
availability of free arachidonic acid. The control of 
the biosynthesis of these compounds in inflam- 
matory cells and other cells depends on the en- 
zymatic release of arachidonic acid from the ~-2 
position of membrane phospholipids. Phospho- 
lipase AZ (PLA2) is the simplest and most obvious 
candidate for the responsible enzyme, although 
many types of phospholipases have been im- 
plicated [ 11. Inhibition of PLA2 may provide an ef- 
fective treatment of inflammatory diseases when 
both the cyclooxygenase and lipooxygenase path- 
ways in the arachidonate cascade are blocked [2]. 
It is known that sn-l-lecithins are pure com- 
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petitive inhibitors for PLA2: they bind with an 
identical affinity to the catalytic site but are not 
hydrolyzed [3]. Substrate analogues containing an 
amide or ether bond at the sn-2 position have been 
reported to be potent reversible PLA2 inhibitors 
[3-61. 
Recent research has concentrated on the role of 
phospholipase AZ-inhibitory proteins as possible 
anti-inflammatory agents. Lipocortins are proteins 
that have been reported to inhibit intracellular 
PLA2. Their inhibitory activity towards PLA2 ap- 
peared to be regulated by phosphorylation [7,8]. 
Lipocortins are 36 kDa anti-inflammatory proteins 
which are inducible by steroids, secreted by cells, 
and thought to act prior to the cyclooxygenase 
pathway by inhibition of a phospholipase AZ. Al- 
though these proteins are thought to interact with 
intracellular PLAZ, their inhibitory activity is 
usually measured with the extracellular porcine 
pancreatic phospholipase AZ. It has been suggested 
that the mechanism of lipocortin action is by direct 
protein-protein interaction [9-l 11. 
Davidson et al. [12] reported that several forms 
of calpactin, which are lipocortin-like proteins, 
just as lipomodulin, macrocortin, renocortin and 
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uteroglobin [ 131, inhibit porcine pancreatic phos- 
pholipase AZ by interaction with phospholipid 
vesicles. Aarsman et al. [14] showed that the hydro- 
lysis of Escherichia coli membrane phospholipids 
by pancreatic PLA2 was inhibited by lipocortin 
from human monocytes in a substrate dependent 
manner. In both cases inhibition was completely 
overcome at higher substrate concentrations. Lipo- 
cortin also inhibited partially purified preparations 
of two intracellular phospholipases AZ isolated 
from rat liver mitochondria and rat platelets. How- 
ever, again the inhibition decreased with increasing 
substrate concentrations [14,15]. From these 
results it was concluded that lipocortin interacts 
with the substrate instead of the enzyme. 
linked with divinylbenzene (S-XI, Bio-Rad; 1.34 mM Cl/g) ac- 
cording to [18]. 
1,2-Dioctanoyl-sn-glycero-3-phosphocholine [19] and ruc- 
2,3-bis-(hexanoylthio)-propylphosphocholine [20] were synthe- 
sized as described. 1,2-Didodecanoyl-sn-glycero-3-phospho- 
glycol was prepared according to De Haas et al. (to be 
published). 
Porcine pancreatic prophospholipase AZ was purified and 
converted into phospholipase AZ (1240 U/mg) as described [21]. 
2.1, Synthesis of the peptides His-Asp-Met-Asn-Lys- Val-Leu- 
Asp-Leu (PI) and Met-GIn-Met-Asn-Lys-Val-Leu-Asp- 
Leu (PII) 
The syntheses of the nonapeptides were performed with a 
Sedimentation equilibrium analysis of mixtures 
of five lipocortin-related phospholipase A2 in- 
hibitors from human placenta and pancreatic phos- 
pholipase A2 indicated weak association between 
enzyme and inhibitor (&? 3 x 10e5 M), insuffi- 
cient to account for the observed inhibition of en- 
zymatic activity [16]. According to these authors, 
their results exclude all mechanisms for inhibition 
in vitro involving complex formation between en- 
zyme and inhibitor. 
semi-automated peptide synthesizer from Bachem (Switzer- 
land), according to [22]. During the synthesis, the side chains of 
aspartic acid, lysine and histidine were protected with the O-But, 
Clz-Z and Tosyl moiety, respectively. After final deprotection 
of the peptides and cleavage from the resin by liquid HF [22], 
the peptides were purified by reversed phase HPLC (Pharmacia) 
using a Cl8 preparative column (Fluka). The peptides were 
pure, as judged by analytical reversed phase HPLC (Cl8 col- 
umn) and amino acid analysis (LKB, England). 
2.2. Ultraviolet-difference spectroscopy 
Recently, experiments with synthetic oligopep- 
tides corresponding to a region of high amino acid 
similarity between uteroglobin, a steroid induced 
rabbit secretory protein, and lipocortin I, showed 
that these peptides have potent phospholipase A2 
inhibitory activity in vitro and striking anti- 
inflammatory effects in vivo [ 171. Almost complete 
inhibition in vitro is reached with stoichiometrical 
amounts of peptide to PLA2. The authors suggest 
that the inhibitory effect of the peptide is exerted 
through an interaction with the enzyme rather than 
with the substrate. 
The affinity of phospholipase AZ for the synthetic peptides PI 
and PI1 was determined by the procedure described in [23] in a 
buffer containing 0.1 M Tris-HCl, pH 8,0.1 M NaCl and 1 mM 
CaClz. The enzyme solution was titrated with the peptides until 
a 2%fold molar excess of the peptides was reached. UV- 
difference spectra were recorded from 265 to 340 nm. 
2.3. Kinetic measurements 
The egg yolk assay was carried out according to the modified 
procedure described in [24]. Kinetic measurements using 
micellar 1,2-dioctanoyl-sn-glycero-3-phosphocholine and mono- 
meric rat-2,3-bis(hexanoylthio)-propyl-phosphocholine w re 
performed as described [20,25]. The assay of porcine pancreatic 
phospholipase A2 on 1-stearoyl-2-[1 ‘-‘4C]arachidonoyl-sn- 
glycero-3-phosphocholine was carried out as described [17]. The 
amount of liberated labelled fatty acid was determined by a 
modified Dole extraction after 4 min reaction time at 37°C [14]. 
Before assaying PLA2 activity the enzyme was preincubated 
with varying amounts of the synthetic peptides PI and PI1 in a 
buffer containing 0.1 M Tris-HCl, pH 8,0.1 M NaCl and 1 mM 
CaC12 at 37°C for 10 min as described [17]. 
2. MATERIALS AND METHODS 2.4. Monolayer experiments 
N”-t-Boc protected amino acids were purchased from Du 
Pont (USA), trifluoroacetic acid from Pierce (USA), N,N-di- 
cyclohexylcarbodiimide and N.N-diisopropylethylamine were 
from Janssen (Belgium) and I-hydroxybenzotriazole was from 
Fluka (Switzerland). N,N-Dimethylformamide and dichlo- 
romethane were from Merck (FRG). Liquid HF was 
from Matheson (USA), acetonitrile from Baker (The Nether- 
lands). I-Stearoyl-2-[1 ‘-?]arachidonoyl-sn-glycero-3-phos- 
phocholine (58 mCi mmol-‘) was obtained from Amersham 
(England). 
N”-t-Boc-leucine resin was prepared by esterification of NW-t- 
Boc-leucine to chloromethylated polystyrene resin 1% cross- 
The zero-order trough with two compartments and the sur- 
face barostat technique used to measure substrate hydrolysis 
were identical with those described in [26] except hat the reac- 
tion compartment was 100 ml. The apparatus was from KSV 
(Finland). Calculation of the velocity of the enzyme reaction 
was performed as described [27]. The surface pressure (r) was 
measured by the Wilhelmy plate method. 
3. RESULTS AND DISCUSSION 
Recently Miele et al. [17] showed that synthetic 
oligopeptides corresponding to a region of high 
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Table 1 
Amino acid composition of the purified synthetic nonapeptides 
PI and PI1 
Amino acid Peptide I Peptide II 
Asx 3.0 (3) 2.1 (2) 
GlX 0.9 (1) 
Val 1.0 (1) 1.0 (1) 
Met 0.9 (1) 2.1 (2) 
Leu 2.1 (2) 2.0 (2) 
His 0.9 (1) 
LYS 1.0 (1) 1.0 (I) 
The expected amount of each amino acid is shown in paren- 
theses 
amino acid sequence similarity between utero- 
globin and lipocortin I have potent phospholipase 
A2 inhibitory activity in vitro and anti- 
inflammatory effects in vivo. We synthesized the 
most potent PLA2 inhibitory peptides PI derived 
from lipocortin I, residues 246-254 (His-Asp-Met- 
Asn-Lys-Val-Leu-Asp-Leu) and PI1 from utero- 
globin, residues 39-47 (Met-Gln-,Met-Asn-Lys-Val- 
Leu-Asp-Leu). PI corresponds with peptide P2 [ 171 
and PI1 corresponds with P3, except that in PI1 the 
C-terminal serine is substituted by a leucine, which 
does not affect the inhibitory potential [17]. 
The nonapeptides were synthesized by conven- 
tional solid phase peptide synthesis methods [28]. 
Amino acid analysis of the purified peptides gave 
the desired amino acid compositions (table 1). To 
determine whether the synthetic peptides PI and 
PI1 show inhibition of extracellular pancreatic 
phospholipase A2 activity this was measured in five 
different kinetic assays. In the egg yolk assay PLA2 
acts on long chain lecithins present as negatively 
charged mixed micelles with sodium deoxycholate 
(DOC). From table 2 it can be seen that in this 
assay both synthetic peptides, even when present in 
large excess, do not inhibit phospholipase A2 ac- 
tivity within the experimental error. In order to 
establish whether the peptides PI and PI1 show in- 
hibition of PLA2 activity we also used micelles of 
1,2-dioctanoyl-sn-glycero-3-phosphocholine as a 
substrate. Also in this much more sensitive assay 
both peptides show no inhibitory effect on PLA2 
activity (table 2). In the same assay I-acyl-2-acyl- 
amino-sn-glycero-3-phosphocholine, a potent tran- 
sition state analogue, shows considerable inhibi- 
tion of phospholipase A2 activity [3]. 
It is known that pancreatic phospholipase A2 
also possesses enzymatic activity toward substrate 
present as monomers [20] although considerably 
lower as compared to micellar substrate. Using 
0.5 mM rue-2,3-bis(hexanoylthio)-propylphospho- 
choline (CMC is 1 mM) as monomeric substrate, it 
can be seen from table 2 that both peptides I and II 
have no effect on PLA2 activity in this assay, 
Table 2 
PLA2 inhibitory activity of the synthetic nonapeptides PI and PI1 in three different kinetic assays 
Assay Peptide Peptide : PLA2 PLA2 residual activity (To) 
Egg yolka PI 3OO:l 90 
PI1 1OO:l 95 
1,2-Dioctanoyl-sn-glycero-3-phosphocholineb 
rue-2,3-Bis(hexanoylthio)- 
propylphosphocholineC 
PI 450: 1 98 
PI 1O:l 99 
PI1 450: 1 98 
PI 4OO:I 100 
PI 2OOO:I 100 
PI1 2OO:l 100 
PI1 1000: 1 100 
a The egg yolk assay was performed as described in section 2 at pH 8, 4O”C, in the presence of DOC 
b The 1,2-dioctanoyl-sn-glycero-3-phosphocholine assay was performed at 45”C, in 0.01 M Tris-HCl, 0.1 M NaCl, 
1 mM CaClt (pH 8) 
’ The rat-2,3-bis(hexanoylthio)-propylphosphocholine assay was performed at 25°C in 0.1 M Tris-HCl, 0.1 M NaCl and 
1 mM CaC12 (pH 8) 
The 070 residual phospholipase A2 activity was calculated from the specific activities of PLA2 measured under the same 
conditions in the presence and absence of the peptides 
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which indicates that the active site of the enzyme is 
not involved in any inhibition event. 
To answer the important question if the lipocor- 
tin derived peptides exert their action on PLA2 on- 
ly when the substrate contains an arachidonic acid 
on the sn-2 position, the peptides PI and PI1 were 
tested in 50 nM concentrations in the in vitro assay 
under the assay conditions in [ 171. 
As can be seen from table 3 phospholipase AZ 
present in an almost one-to-one ratio of enzyme 
(36 nM) to peptide (50 nM) releases similar 
amounts of [l ‘-‘4C]arachidonic acid as compared 
to PLA2 without preincubation with the peptide. 
Also an almost 30000-fold excess of peptide 
(1 mM) present during preincubation with the en- 
zyme, does not result in a detectable inhibition of 
PLA2. 
Finally, monolayer experiments were performed 
to check if a large excess of peptide is able to pre- 
vent penetration into and hydrolysis of the 
negatively charged substrate 1,2-didodecanoyl-sn- 
glycero-3-phosphoglycol. Before injection of 
PLA2 in the reaction compartment, 0.5 mg (4 PM) 
peptide was injected, which did not result in an in- 
crease of the surface pressure. At a surface pressure 
of 30 dynes/cm, the hydrolytic activity of PLA2 
(0.28 nM) in the absence of peptide was 
13.0 mm/min per pg protein injected. In the 
presence of the synthetic peptides PI and PII, 
PLA2 reached, in a similar experiment, a velocity 
of 13.3 mm/min per pg protein. These results show 
that there is no significant inhibitory influence of 
the peptides PI and PI1 on the hydrolytic and 
penetrating properties of phospholipase AZ. 
In addition direct binding studies using UV- 
difference spectroscopy were performed to detect 
possible interactions between porcine pancreatic 
PLA2 and each of these peptides. It is well known 
that upon binding of monomeric substrate 
analogues to PLA2 difference spectra are gener- 
ated originating from Tyr69 perturbation close to 
the active site [29]. Similarly interaction of micellar 
substrate analogues with PLA2 results in dif- 
ference spectra typical for Tyr69 and Trp3 pertur- 
bation, residues known to be part of the lipid bin- 
ding domain (LBD) [29]. Titration of either pep- 
tide PI or PI1 to PLA2 up to a 25-fold molar excess 
does not give rise to any difference spectrum, 
strongly suggesting that the peptides have no af- 
finity for PLA2 (not shown). However, an interac- 
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Table 3 
PLA2 inhibitory activity of the synthetic nonapeptides PI and 
PI1 on I-stearoyl-2-[l ‘-‘4C]arachidonoyl-sn-glycero-3-phos- 
phocholine (PC) 
Assay condition? Percentage radioactivity 
liberated by PLA2 
10 ,uM PC, no PLA2 0.2 
10 PM PC, 36 nM PLA2 24 
1OpM PC, 36 nM PLA2, 50 nM PI 32 
10,~M PC, 36 nM PLA2, 1 mM PI 33 
10,~M PC, 36 nM PLA2, 50 nM PI1 24 
10pM PC, 36 nM PLA2,l mM PI1 23 
lO,zM PC, 1.4,uM PLA2 70 
a The assay was performed in a final volume of 50 ~1 in the buf- 
fer described in [17], containing 1 mM DOC. The DOC was 
not present during the preincubation of the enzyme with the 
peptides 
tion of the peptides with non-aromatic residues, 
e.g. by charge interaction cannot be excluded. 
It is obvious from these results that the peptides 
PI and PI1 do not inhibit phospholipase A2 activity 
in any in vitro assay after preincubation of the en- 
zyme with the peptides. This strongly supports the 
results recently reported by Ahn et al. [ 161, in 
which the affinity between enzyme and lipocortin 
was measured. The reported & value excludes all 
mechanisms for inhibition in vitro involving com- 
plex formation between enzyme and inhibitor [ 161. 
Therefore it is unlikely that the peptides PI and PI1 
derived from lipocortin I are inhibitors, acting by 
binding to the enzyme, as suggested by Miele et al. 
[17]. The results also do not support the model 
which proposes the binding of the inhibitor to the 
substrate instead of to the enzyme [12-151, as the 
mechanism of lipocortin action. Even when only a 
1.6fold molar excess of peptide is present over the 
substrate in the rat-2,3-bis(haxanoylthio)-propyl- 
phosphocholine assay, no decrease in PLA2 activi- 
ty was observed (table 2). This finding confirms the 
data obtained with monolayer experiments: both 
peptides do not interact with phospholipids in such 
a way that phospholipase AZ activity is inhibited. 
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